Filing Details
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) filed a Form 8-K with the Securities and Exchange Commission on August 05, 2026, disclosing a material event.
8k filedNASDAQ:CTXR
Citius Pharmaceuticals, Inc. (CTXR) Reports Material Event to SEC
Filing Details Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) filed a Form 8-K with the Securities and Exchange Commission on August 05, 2026, disclosing a material event. Market…
Market Context
Citius Pharmaceuticals, Inc.'s stock currently trades at $0.78 with a market capitalization of $13.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Citius Pharmaceuticals, Inc.'s stock.
All SEC filings for Citius Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CTXR Stock Page
Frequently Asked Questions
Where can I read CTXR's SEC filings?
Browse all filings on our CTXR SEC filings page.
What types of SEC filings does Citius Pharmaceuticals, Inc. file?
Public companies like Citius Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.